S&P 500   3,380.40 (+0.52%)
DOW   27,893.53 (+0.40%)
QQQ   281.65 (+1.37%)
AAPL   116.63 (+0.71%)
MSFT   212.20 (+0.89%)
FB   266.53 (+1.77%)
GOOGL   1,479.13 (+0.92%)
AMZN   3,190.33 (+1.32%)
TSLA   436.93 (+1.85%)
NVDA   544.92 (+0.68%)
BABA   291.31 (-0.91%)
CGC   14.31 (-0.07%)
MU   47.76 (+1.70%)
GE   6.24 (+0.16%)
AMD   83.42 (+1.74%)
T   28.52 (+0.04%)
F   6.70 (+0.60%)
ACB   4.58 (-1.51%)
GILD   63.19 (+0.00%)
NFLX   508.42 (+1.68%)
DIS   124.63 (+0.44%)
BA   171.01 (+3.48%)
BAC   24.20 (+0.46%)
S&P 500   3,380.40 (+0.52%)
DOW   27,893.53 (+0.40%)
QQQ   281.65 (+1.37%)
AAPL   116.63 (+0.71%)
MSFT   212.20 (+0.89%)
FB   266.53 (+1.77%)
GOOGL   1,479.13 (+0.92%)
AMZN   3,190.33 (+1.32%)
TSLA   436.93 (+1.85%)
NVDA   544.92 (+0.68%)
BABA   291.31 (-0.91%)
CGC   14.31 (-0.07%)
MU   47.76 (+1.70%)
GE   6.24 (+0.16%)
AMD   83.42 (+1.74%)
T   28.52 (+0.04%)
F   6.70 (+0.60%)
ACB   4.58 (-1.51%)
GILD   63.19 (+0.00%)
NFLX   508.42 (+1.68%)
DIS   124.63 (+0.44%)
BA   171.01 (+3.48%)
BAC   24.20 (+0.46%)
S&P 500   3,380.40 (+0.52%)
DOW   27,893.53 (+0.40%)
QQQ   281.65 (+1.37%)
AAPL   116.63 (+0.71%)
MSFT   212.20 (+0.89%)
FB   266.53 (+1.77%)
GOOGL   1,479.13 (+0.92%)
AMZN   3,190.33 (+1.32%)
TSLA   436.93 (+1.85%)
NVDA   544.92 (+0.68%)
BABA   291.31 (-0.91%)
CGC   14.31 (-0.07%)
MU   47.76 (+1.70%)
GE   6.24 (+0.16%)
AMD   83.42 (+1.74%)
T   28.52 (+0.04%)
F   6.70 (+0.60%)
ACB   4.58 (-1.51%)
GILD   63.19 (+0.00%)
NFLX   508.42 (+1.68%)
DIS   124.63 (+0.44%)
BA   171.01 (+3.48%)
BAC   24.20 (+0.46%)
S&P 500   3,380.40 (+0.52%)
DOW   27,893.53 (+0.40%)
QQQ   281.65 (+1.37%)
AAPL   116.63 (+0.71%)
MSFT   212.20 (+0.89%)
FB   266.53 (+1.77%)
GOOGL   1,479.13 (+0.92%)
AMZN   3,190.33 (+1.32%)
TSLA   436.93 (+1.85%)
NVDA   544.92 (+0.68%)
BABA   291.31 (-0.91%)
CGC   14.31 (-0.07%)
MU   47.76 (+1.70%)
GE   6.24 (+0.16%)
AMD   83.42 (+1.74%)
T   28.52 (+0.04%)
F   6.70 (+0.60%)
ACB   4.58 (-1.51%)
GILD   63.19 (+0.00%)
NFLX   508.42 (+1.68%)
DIS   124.63 (+0.44%)
BA   171.01 (+3.48%)
BAC   24.20 (+0.46%)
Log in
NASDAQ:RARE

Ultragenyx Pharmaceutical Stock Forecast, Price & News

$83.40
+1.21 (+1.47 %)
(As of 10/1/2020 09:45 AM ET)
Add
Compare
Today's Range
$82.67
Now: $83.40
$83.40
50-Day Range
$72.98
MA: $82.03
$87.96
52-Week Range
$31.99
Now: $83.40
$91.77
Volume364 shs
Average Volume507,253 shs
Market Capitalization$5.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.23
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
Read More
Ultragenyx Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.27 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$103.71 million
Book Value$11.32 per share

Profitability

Net Income$-402,730,000.00
Net Margins-188.51%

Miscellaneous

EmployeesN/A
Market Cap$5.05 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$83.40
+1.21 (+1.47 %)
(As of 10/1/2020 09:45 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

How has Ultragenyx Pharmaceutical's stock been impacted by COVID-19?

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RARE shares have increased by 83.9% and is now trading at $83.40.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Ultragenyx Pharmaceutical?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ultragenyx Pharmaceutical
.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Ultragenyx Pharmaceutical
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) released its earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($0.82) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.56) by $0.74. The biopharmaceutical company earned $61.71 million during the quarter, compared to analyst estimates of $40.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 56.12% and a negative net margin of 188.51%.
View Ultragenyx Pharmaceutical's earnings history
.

What price target have analysts set for RARE?

15 equities research analysts have issued 1 year target prices for Ultragenyx Pharmaceutical's stock. Their forecasts range from $64.00 to $99.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $82.38 in the next twelve months. This suggests that the stock has a possible downside of 1.2%.
View analysts' price targets for Ultragenyx Pharmaceutical
.

Are investors shorting Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical saw a decrease in short interest in August. As of August 14th, there was short interest totaling 6,840,000 shares, a decrease of 14.7% from the July 30th total of 8,020,000 shares. Based on an average daily trading volume, of 450,900 shares, the short-interest ratio is currently 15.2 days. Currently, 12.2% of the company's shares are sold short.
View Ultragenyx Pharmaceutical's Short Interest
.

Who are some of Ultragenyx Pharmaceutical's key competitors?

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals PLC- (GWPH) and QUALCOMM (QCOM).

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the following people:
  • Emil D. Kakkis, President, Chief Executive Officer & Director
  • Wladimir Hogenhuis, Chief Operating Officer
  • Shalini Sharp, Chief Financial Officer & Executive Vice President
  • Dennis Karl Huang, Chief Technical Operations Officer & Senior VP
  • Eric Crombez, Chief Medical Officer

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $83.40.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $5.05 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.